% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Boschheidgen:284932,
author = {M. Boschheidgen and P. Albers$^*$ and H.-P. Schlemmer$^*$
and S. Hellms and D. Bonekamp$^*$ and A. Sauter and B.
Hadaschik$^*$ and A. Krilaviciute$^*$ and J. P. Radtke and
P. Seibold$^*$ and J. Lakes and C. Arsov and J. E. Gschwend
and K. Herkommer and M. Makowski and M. A. Kuczyk and F.
Wacker and N. Harke and J. Debus and S. A. Körber and A.
Benner$^*$ and G. Kristiansen and F. L. Giesel and G. Antoch
and R. Kaaks$^*$ and N. Becker$^*$ and L. Schimmöller},
title = {{M}ultiparametric {M}agnetic {R}esonance {I}maging in
{P}rostate {C}ancer {S}creening at the {A}ge of 45 {Y}ears:
{R}esults from the {F}irst {S}creening {R}ound of the
{PROBASE} {T}rial.},
journal = {European urology},
volume = {85},
number = {2},
issn = {0302-2838},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DKFZ-2023-02132},
pages = {105-111},
year = {2024},
note = {2024 Feb;85(2):105-111},
abstract = {Magnetic resonance imaging (MRI) has been suggested as a
tool for guiding biopsy recommendations in prostate cancer
(PC) screening.To determine the performance of
multiparametric MRI (mpMRI) in young men at age 45 yr who
participated in a PC screening trial (PROBASE) on the basis
of baseline prostate-specific antigen (PSA).Participants
with confirmed PSA ≥3 ng/ml were offered mpMRI followed by
MRI/transrectal ultrasound fusion biopsy (FBx) with targeted
and systematic cores. mpMRI scans from the first screening
round for men randomised to an immediate PSA test in PROBASE
were evaluated by local readers and then by two reference
radiologists (experience >10 000 prostate MRI examinations)
blinded to the histopathology. The PROBASE trial is
registered as ISRCTN37591328 OUTCOME MEASUREMENTS AND
STATISTICAL ANALYSIS: The local and reference Prostate
Imaging-Data and Reporting System (PI-RADS) scores were
compared, and the sensitivity, negative predictive value
(NPV), and accuracy were calculated for both readings for
different cutoffs (PI-RADS 3 vs 4).Of 186 participants, 114
underwent mpMRI and FBx. PC was detected in 47 $(41\%),$ of
whom 33 $(29\%)$ had clinically significant PC (csPC;
International Society of Urological Pathology grade group
≥2). Interobserver reliability between local and reference
PI-RADS scores was moderate (k = 0.41). At a cutoff of
PI-RADS 4, reference reading showed better performance for
csPC detection (sensitivity $79\%,$ NPV $91\%,$ accuracy of
$85\%)$ than local reading (sensitivity $55\%,$ NPV $80\%,$
accuracy $68\%).$ Reference reading did not miss any PC
cases for a cutoff of PI-RADS <3. If PI-RADS ≥4 were to be
used as a biopsy cutoff, mpMRI would reduce negative
biopsies by $68\%$ and avoid detection of nonsignificant PC
in $71\%$ of cases.Prostate MRI in a young screening
population is difficult to read. The MRI accuracy of for
csPC detection is highly dependent on reader experience, and
double reading might be advisable. More data are needed
before MRI is included in PC screening for men at age 45
yr.Measurement of prostate specific antigen (PSA) is an
effective screening test for early detection of prostate
cancer (PC) and can reduce PC-specific deaths, but it can
also lead to unnecessary biopsies and treatment. Magnetic
resonance imaging (MRI) after a positive PSA test has been
proposed as a way to reduce the number of biopsies, with
biopsy only recommended for men with suspicious MRI
findings. Our results indicate that MRI accuracy is moderate
for men aged 45 years but can be increased by a second
reading of the images by expert radiologists. For broad
application of MRI in routine screening, double reading may
be advisable.},
keywords = {Magnetic resonance imaging, Interventional (Other) /
Multiparametric magnetic resonance imaging (Other) /
Prostatic neoplasms (Other) / Screening (Other)},
cin = {C130 / E010 / ED01 / C060 / C020},
ddc = {610},
cid = {I:(DE-He78)C130-20160331 / I:(DE-He78)E010-20160331 /
I:(DE-He78)ED01-20160331 / I:(DE-He78)C060-20160331 /
I:(DE-He78)C020-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37863727},
doi = {10.1016/j.eururo.2023.09.027},
url = {https://inrepo02.dkfz.de/record/284932},
}